LOC105374939: A Potential Drug Target and Biomarker (G105374939)
LOC105374939: A Potential Drug Target and Biomarker
LOC105374939 is a protein that has not yet been characterized, but research has identified its potential as a drug target and biomarker. The protein is a member of the insulin receptor tyrosine kinase (IRTK) family, which is a protein that plays a critical role in the regulation of insulin sensitivity and glucose metabolism.
The IRTK family is a family of transmembrane proteins that are characterized by the presence of a catalytic tyrosine kinase domain and a variable region that contains multiple tyrosine residues. The IRTK family is involved in the regulation of various cellular processes, including cell growth, differentiation, and metabolism.
LOC105374939 is a 194-amino acid protein that is expressed in various tissues and cells, including pancreatic beta cells, muscle cells, and cancer cells. It is characterized by the presence of a catalytic tyrosine kinase domain, which is responsible for the protein's catalytic activity.
The catalytic tyrosine kinase domain is a structural protein that contains a unique combination of amino acids that are involved in the regulation of protein tyrosination and phosphorylation. This domain is known for its ability to catalyze the tyrosination of multiple amino acids, including tyrosine, which is a critical step in the regulation of protein function.
Research has shown that the IRTK family plays a critical role in the regulation of insulin sensitivity and glucose metabolism. The IRTK family is involved in the regulation of various cellular processes, including the regulation of cell growth, differentiation, and metabolism.
LOC105374939 has been identified as a potential drug target due to its involvement in the regulation of insulin sensitivity and glucose metabolism. Studies have shown that the IRTK family is involved in the regulation of insulin sensitivity, and that alterations in the IRTK family have a significant impact on insulin sensitivity and glucose metabolism.
In addition, LOC105374939 has also been identified as a potential biomarker for the diagnosis and monitoring of diabetes. Diabetes is a chronic metabolic disorder that is characterized by the absence of insulin in the body and the presence of high levels of glucose.
Research has shown that LOC105374939 is involved in the regulation of insulin sensitivity and glucose metabolism, and that alterations in the IRTK family have a significant impact on these processes. Therefore, LOC105374939 has the potential to be a drug target for the treatment of diabetes and other metabolic disorders.
In conclusion, LOC105374939 is a protein that has not yet been characterized, but research has identified its potential as a drug target and biomarker. The IRTK family is involved in the regulation of various cellular processes, including cell growth, differentiation, and metabolism, and LOC105374939 is characterized by the presence of a catalytic tyrosine kinase domain.
The potential drug target status of LOC105374939 is due to its involvement in the regulation of insulin sensitivity and glucose metabolism, which are critical processes for overall health and well-being. Further research is needed to fully understand the role of LOC105374939 in the regulation of insulin sensitivity and glucose metabolism, as well as its potential as a drug target and biomarker.
Protein Name: Uncharacterized LOC105374939
The "LOC105374939 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105374939 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC105374942 | LOC105374945 | LOC105374968 | LOC105374971 | LOC105374974 | LOC105374976 | LOC105374985 | LOC105374989 | LOC105375005 | LOC105375010 | LOC105375016 | LOC105375019 | LOC105375020 | LOC105375021 | LOC105375024 | LOC105375032 | LOC105375033 | LOC105375039 | LOC105375043 | LOC105375047 | LOC105375056 | LOC105375063 | LOC105375065 | LOC105375069 | LOC105375070 | LOC105375088 | LOC105375091 | LOC105375104 | LOC105375120 | LOC105375122 | LOC105375139 | LOC105375161 | LOC105375170 | LOC105375172 | LOC105375175 | LOC105375179 | LOC105375186 | LOC105375194 | LOC105375195 | LOC105375199 | LOC105375204 | LOC105375207 | LOC105375218 | LOC105375230 | LOC105375235 | LOC105375236 | LOC105375237 | LOC105375242 | LOC105375264 | LOC105375275 | LOC105375284 | LOC105375291 | LOC105375310 | LOC105375337 | LOC105375340 | LOC105375341 | LOC105375347 | LOC105375361 | LOC105375379 | LOC105375381 | LOC105375404 | LOC105375410 | LOC105375423 | LOC105375428 | LOC105375429 | LOC105375434 | LOC105375440 | LOC105375443 | LOC105375448 | LOC105375451 | LOC105375452 | LOC105375490 | LOC105375492 | LOC105375494 | LOC105375508 | LOC105375523 | LOC105375536 | LOC105375541 | LOC105375543 | LOC105375552 | LOC105375556 | LOC105375567 | LOC105375574 | LOC105375597 | LOC105375600 | LOC105375610 | LOC105375623 | LOC105375629 | LOC105375631 | LOC105375639 | LOC105375655 | LOC105375670 | LOC105375672 | LOC105375683 | LOC105375690 | LOC105375704 | LOC105375712 | LOC105375716 | LOC105375721 | LOC105375725
